Table 1. Search strategy.
GLP: glucagon-like peptide-1; GIP: glucose-dependent insulinotropic polypeptide; RCT: randomized controlled trial.
| Database | Search strategy | No. of records before applying filters | Filters applied | No. of records after applying filters |
| PubMed | ((GLP 1 agonists OR semaglutide OR dulaglutide OR exenatide OR liraglutide OR lixisenatide OR (("Glucagon-Like Peptide 1/adverse effects"[Majr] OR "Glucagon-Like Peptide 1/agonists"[Majr] OR "Glucagon-Like Peptide 1/analogs and derivatives"[Majr] OR "Glucagon-Like Peptide 1/drug effects"[Majr] OR "Glucagon-Like Peptide 1/pharmacology"[Majr] OR "Glucagon-Like Peptide 1/therapeutic use"[Majr])) OR ("Glucagon-Like Peptide 1/adverse effects"[Mesh:NoExp] OR "Glucagon-Like Peptide 1/agonists"[Mesh:NoExp] OR "Glucagon-Like Peptide 1/analogs and derivatives"[Mesh:NoExp] OR "Glucagon-Like Peptide 1/drug effects"[Mesh:NoExp] OR "Glucagon-Like Peptide 1/pharmacology"[Mesh:NoExp] OR "Glucagon-Like Peptide 1/therapeutic use"[Mesh:NoExp])) AND (Tirzepatide OR glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 (GLP-1) receptor agonist OR Twincretin OR dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) receptor agonist OR (("Gastric Inhibitory Polypeptide/adverse effects"[Majr] OR "Gastric Inhibitory Polypeptide/agonists"[Majr] OR "Gastric Inhibitory Polypeptide/analogs and derivatives"[Majr] OR "Gastric Inhibitory Polypeptide/drug effects"[Majr] OR "Gastric Inhibitory Polypeptide/pharmacology"[Majr] OR "Gastric Inhibitory Polypeptide/therapeutic use"[Majr])) OR ("Gastric Inhibitory Polypeptide/adverse effects"[Mesh:NoExp] OR "Gastric Inhibitory Polypeptide/agonists"[Mesh:NoExp] OR "Gastric Inhibitory Polypeptide/analogs and derivatives"[Mesh:NoExp] OR "Gastric Inhibitory Polypeptide/drug effects"[Mesh:NoExp] OR "Gastric Inhibitory Polypeptide/pharmacology"[Mesh:NoExp] OR "Gastric Inhibitory Polypeptide/therapeutic use"[Mesh:NoExp])) AND (Diabetes Mellitus OR Diabetes OR (("Diabetes Mellitus, Type 2/drug therapy"[Majr] OR "Diabetes Mellitus, Type 2/therapy"[Majr])) OR ("Diabetes Mellitus, Type 2/drug therapy"[Mesh:NoExp] OR "Diabetes Mellitus, Type 2/therapy"[Mesh:NoExp])) AND (Cardiovascular outcomes OR Cardiovascular events OR Major Cardiovascular adverse events OR Cardiac OR Cardiovascular OR MACE OR (("Cardiovascular Diseases/drug therapy"[Majr] OR "Cardiovascular Diseases/prevention and control"[Majr] OR "Cardiovascular Diseases/therapy"[Majr])) OR ("Cardiovascular Diseases/drug therapy"[Mesh:NoExp] OR "Cardiovascular Diseases/prevention and control"[Mesh:NoExp] OR "Cardiovascular Diseases/therapy"[Mesh:NoExp]))) OR ((GLP 1 agonists OR semaglutide OR dulaglutide OR exenatide OR liraglutide OR lixisenatide) AND (Diabetes Mellitus OR Diabetes) AND (Cardiovascular outcomes OR Cardiovascular events OR Major Cardiovascular adverse events OR Cardiac OR Cardiovascular OR MACE)) OR ((Tirzepatide OR glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 (GLP-1) receptor agonist OR Twincretin OR dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) receptor agonist) AND (Diabetes Mellitus OR Diabetes) AND (Cardiovascular outcomes OR Cardiovascular events OR Major Cardiovascular adverse events OR Cardiac OR Cardiovascular OR MACE)) | 3251 | Free full text, clinical trial, meta-analysis, RCT, review, systematic review, English, 2018-2023 | 583 |
| Google Scholar | (GLP 1 agonists OR dual GLP 1/GIP agonist OR (GLP 1 agonists AND dual GLP 1/GIP agonist)) AND diabetes mellitus type 2 AND (cardiovascular effects OR cardiovascular outcomes) | 1310 | 2018-2023, English | 760 |